Halozyme Announces Janssen Submission Of Applications In US And EU Seeking Approval Of DARZALEX FASPRO(TM)/ DARZALEX Subcutaneous (SC) Formulation Utilizing ENHANZE Technology, Combination With Pomalidomide And Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma

Source :: PR Newswire. November 12, 2020
Publication Year :: 2020
Abstract: SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the Janssen Pharmaceutical Companies submitted regulatory applications to the U.S. Food and Drug Administration (FDA) [...]

Subjects :: United States. Food and Drug Administration -- Technology application
Central nervous system depressants -- Technology application
Diseases -- Relapse
Dexamethasone -- Technology application
Multiple myeloma -- Drug therapy
Drug approval -- Technology application
Technology application
Business
News, opinion and commentary
European Union -- Technology application
Darzalex (Medication)

Tools